Anti-ChAT-SAP References

Cat #IT-42


Ashkenazi SL, Polis B, David O, Morris G (2021) Striatal cholinergic interneurons exert inhibition on competing default behaviours controlled by the nucleus accumbens and dorsolateral striatum. Eur J Neurosci 53(7):2078-2089. doi: 10.1111/ejn.14873

Objective: To determine whether cholinergic interneurons contribute to the competition between both ventral and dorsolateral control systems.
Summary: Findings indicate a central role of cholinergic interneurons in regulating motivational impact on striatally controlled behaviors.
Dose:   Anti-ChAT-SAP was diluted to 0.5 μg/μl in phosphate buffer saline and 0.5 μl were injected in each injection site.


Loftén A, Adermark L, Ericson M, & Söderpalm B. An acetylcholine-dopamine interaction in the nucleus accumbens and its involvement in ethanol’s dopamine-releasing effect. (2020)  Addict Biol e12959. doi: 10.1111/adb.12959

Summary: Basal extracellular levels of dopamine within the nucleus accumbens are not sustained by muscarinic acetylcholine, whereas accumbal Cholinergic interneurons-ACh are involved in mediating ethanol-induced dopamine release.
Dose: Anti-ChAT-SAP or Rabbit IgG-SAP were infused  at a flow rate of 0.05 μl/min for 10 min giving a total volume of 0.5 μl.


Weiner GA, Shah SH, Angelopoulos CM, Bartakova AB, Pulido RS, Murphy A, Nudleman E, Daneman R, Goldberg JL. Cholinergic neural activity directs retinal layer-specific angiogenesis and blood retinal barrier formation. (2019) Nat Commun 10(1):2477. doi: 10.1038/s41467-019-10219-8

Objective:  To determine which neurons are responsible for angiogenesis and blood retinal barrier formation.
Summary:  Anti-ChAT-SAP reduces SAC (starburst amacrine cell) number and inhibits deep-layer angiogenesis.
Dose:  Anti-ChAT-SAP or control Rabbit-IgG-SAP was injected intravitreally at P3 and P11 (0.12 mg/mL in PBS).


Liu A, Aoki S, Wickens J. (2017) A Streamlined Method for the Preparation of Gelatin Embedded Brains and Simplified Organization of Sections for Serial Reconstructions. BIO-PROTOCOL 7.

Xiao H, Li M, Cai J, Li N, Zhou M, Wen P, Xie Z, Wang Q, Chang J, Zhang W. (2017) Selective Cholinergic Depletion of Pedunculopontine Tegmental Nucleus Aggravates Freezing of Gait in Parkinsonian Rats. Neurosci Lett 659:92-98. PMID: 28803956


Abudukeyoumu N, Garcia-Munoz M, Jaidar OP, Arbuthnott G (2016) Striatal cholinergic interneurons: their depletion and its progression. Soc Neurosci Meeting Abstract 245.09


Aoki S, Liu AW, Zucca A, Zucca S, Wickens JR. (2015) Role of striatal cholinergic interneurons in set-shifting in the rat. J Neurosci 35(25):9424-9431. (Targeting Trends 15q3)

Aoki S, Wickens JR. (2015) Anti-ChAT-SAP elucidates a causal role in behavioral flexibility. Targeting Trends 16(4).

Kucinski A. (2015) Impairments in gait, posture and complex movement control in rats modeling the multi-system, cholinergic-dopaminergic losses in Parkinson’s Disease. Targeting Trends 16(1).

Xu M, Kobets A, Du JC, Lennington J, Li L, Banasr M, Duman RS, Vaccarino FM, DiLeone RJ, Pittenger C. (2015) Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome. Proc Natl Acad Sci U S A 112(3):893-898. (Targeting Trends 15q3)


LaPlante F. (2013) Role of cholinergic neurons in the nucleus accumbens and their involvement in schizophrenic pathology. Targeting Trends 14(1).

Laplante F, Dufresne MM, Ouboudinar J, Ochoa-Sanchez R, Sullivan RM. (2013) Reduction in cholinergic interneuron density in the nucleus accumbens attenuates local extracellular dopamine release in response to stress or amphetamine. Synapse 67(1):21-29. (Targeting Trends 13q2)


Laplante F, Zhang ZW, Huppe-Gourgues F, Dufresne MM, Vaucher E, Sullivan RM. (2012) Cholinergic depletion in nucleus accumbens impairs mesocortical dopamine activation and cognitive function in rats. Neuropharmacology 63(6):1075-1084. (Targeting Trends 12q4)


Laplante F, Lappi DA, Sullivan RM (2011) Cholinergic depletion in the nucleus accumbens: Effects on amphetamine response and sensorimotor gating. Prog Neuropsychopharmacol Biol Psychiatry 35(2):501-509. (Targeting Trends 11q1)